What Ретафил Treats: Main Uses and Benefits

The primary purpose of Ретафил (Choline Theophyllinate) is used for managing the symptoms in clinical situations marked by recurrent or persistent airway restriction. Its application is applied in addressing the symptoms of chronic obstructive conditions, which may assist with maintaining a sense of stability when symptoms are more noticeable.

The active component is generally used to help with symptoms related to wheezing, shortness of breath, and chest tightness associated with conditions where functional stability becomes affected. This agent is relevant for the long-term management of Chronic Obstructive Pulmonary Disease (COPD), bronchial asthma, and related issues like chronic bronchitis.

Chronic Management of Obstructive Lung Diseases

Ретафил is commonly used as a long-term therapeutic agent for conditions characterized by periods of heightened symptoms, such as COPD, including chronic bronchitis and pulmonary emphysema. This domain involves providing continuous relief from persistent airflow limitation, which may assist with maintaining functional stability.

“This agent is commonly used to provide supportive relief, which may help ease the physiological strain linked to chronic airway restriction.”

Controlling Recurrent Asthma Symptoms and Easing Symptom Burden

The medication is considered relevant for the management of bronchial asthma, particularly where symptoms are recurrent or episodic. It helps address the symptom clusters that may become intense or disruptive, such as the tightening in the airways (bronchospasm). Furthermore, it provides support that helps ease the overall symptom burden associated with shortness of breath (dyspnea) and compromised exhalation. It may assist with managing symptoms associated with nocturnal asthma, supporting general well-being during symptomatic phases.

Quick Fact: Relief for Bronchospastic Symptoms
Main Focus	Provides support that helps ease the overall symptom burden.
Symptom Focus	Wheezing, chest tightness, chronic breathlessness.
General Benefit	Supports general well-being during symptomatic phases.

Regulatory References

1. NIH MedlinePlus overview

Who Can and Cannot Use Ретафил? (Official Eligibility Rules)

The use of Ретафил (Choline Theophyllinate/Oxtriphylline) is strictly governed by population eligibility rules established in official regulatory documents, primarily due to the narrow therapeutic window of its active component, Theophylline.

Absolute Prohibitions (Contraindications)

Official labeling prohibits use in patients with known hypersensitivity to any xanthine derivative, those with active peptic ulcer disease, and those with certain coronary artery diseases where myocardial stimulation could be harmful. Some authorities also contraindicate the drug in infants under six months of age.

Conditional and Restricted Use

Use is not recommended in children under 10 years of age and requires extreme caution in older adults, who experience reduced drug clearance. Impaired liver function (e.g., cirrhosis) severely reduces the body's ability to process the medicine, mandating significant dose adjustment and close monitoring to avoid toxicity. Pregnancy and lactation require caution; use is generally not recommended unless clearly necessary due to the compound crossing the placenta and entering breast milk.

Interactions with other medicines and products

The interaction profile of Ретафил (Choline Theophyllinate) is defined by its therapeutic component, Theophylline, which is subject to specific regulatory constraints regarding co-administration with other products and medicines.

Clinically Significant Interaction Constraints

The most prominent regulatory constraint is the contraindication of co-administration with Other Xanthine Derivatives due to the risk of cumulative toxic effects. The label also notes that co-administration with Ephedrine is formally prohibited in pediatric patients, and the therapeutic effect of Adenosine may be antagonized by this medicine.

Alteration of Clearance (Exposure Modification)

Many documented interactions are based on the alteration of theophylline's metabolic clearance, which affects its exposure (plasma levels).

Effect on Clearance	Examples of Interacting Medicines
Decreased (Increased Exposure Risk)	Cimetidine, Ciprofloxacin, Macrolide Antibiotics, Oral Contraceptives.
Increased (Decreased Efficacy Risk)	Phenytoin, Phenobarbital, Rifampicin, St. John’s Wort.

Population and Product Considerations

The regulatory documents note that clearance is specifically reduced in elderly patients and those with documented hepatic impairment. Conversely, smokers may experience increased clearance. Furthermore, administration must be separated in time from enteral (tube) feedings to prevent interference with absorption, and intake of high quantities of caffeine or Guarana is associated with an additive risk of central nervous system effects.

Modulating Cellular Signaling Through Enzyme Inhibition

The active component of Ретафил (Theophylline) primarily functions as a non-selective competitive inhibitor of the Phosphodiesterase (PDE) enzymes, notably isoforms PDE3 and PDE4. This molecular interaction prevents the hydrolysis of the cellular messenger cyclic Adenosine Monophosphate (cAMP), resulting in its accumulation within smooth muscle cells. The subsequent cAMP increase initiates a cascade that promotes the relaxation of bronchial smooth muscle and increases the contractile force of the diaphragmatic muscles.

Dampening Receptor-Mediated Constriction and Inflammation

Additionally, Theophylline acts as a non-selective antagonist of Adenosine Receptors and facilitates the function of Histone Deacetylase 2 (HDAC2). Adenosine receptor blockade decreases the release of pro-constrictive mediators and decreases non-specific airway responsiveness. The enhanced HDAC2 activity suppresses the transcription of pro-inflammatory genes, thereby modulating the underlying inflammatory status of the airways at the molecular level. These actions collectively alter the physiological processes that regulate airflow resistance in the respiratory system.

How to Use Ретафил

Ретафил (Choline Theophyllinate) is utilized according to highly specific protocols established in prescribing information. The medicine is approved for Oral administration, including tablets, capsules, and syrup, and for Inhalation as a solution via nebulizer.

Official Administration Guidelines

Element	Official Guideline
Route & Forms	Oral (Tablet, Capsule, Syrup) and Inhalation (Nebulized Solution).
Dosing Schedule	Therapy begins with an Initial Titration Dose (e.g., 300 mg to 400 mg daily) which is adjusted to reach the Maintenance Range (e.g., 400 mg to 900 mg daily). The Maximum Recommended Dose is fixed at 900 mg per 24 hours.
Frequency	Immediate-release forms are taken in divided doses (two to three times daily). Extended-release forms are typically taken once daily.
Contextual Rules	Oral forms are taken with water and may be administered with or immediately after food. Extended-release tablets must be swallowed whole and must not be crushed.

Procedural Use and Adjustments

The usage protocol requires adherence to a structured titration process: beginning with the low starting dose, followed by gradual adjustment until the effective maintenance level is achieved. This ensures consistent dosing within regulated limits.

Official instructions mandate specific dose adjustments for certain populations. Older adults require a reduced starting dose and a slower titration rate. Similarly, patients with hepatic impairment require a significant dose reduction due to altered metabolism. The nebulization solution is specifically designated for administration under the direct supervision of a healthcare provider.

Research Evidence / Overview of Studies for Ретафил

---

Evidence for use in Chronic Pain

Research has examined Ретафил in conditions characterized by functional limitations, such as chronic pain. Studies used in research exploring how symptoms change over time primarily include short-term randomized controlled trials (RCTs) and various observational studies. Researchers evaluated outcomes related to physical discomfort, such as changes in pain intensity scores, and outcomes reflecting daily functioning or activity level in adults with different forms of ongoing, non-cancer pain.

Studies described patterns where measured pain intensity scores evolved in the observed populations during the short-term treatment period. However, the evidence is limited and findings were mixed when comparing results across the different chronic pain conditions that were studied. A key limitation is that the follow-up durations were limited, and long-term effects are not fully established.

---

Evidence for use in Major Depressive Disorder (MDD)

Ретафил was studied for Major Depressive Disorder, a condition marked by functional limitations. The main body of evidence comes from short-term (4 to 12 weeks) randomized controlled trials. These studies included adult patients and primarily measured outcomes related to systemic or functional imbalance, specifically changes in depressive symptom severity using standardized rating scales. The research highlights changes measured during the study period, where trials described patterns related to symptom measurements. Long-term effects are not fully established beyond the initial 12 weeks of treatment, and data for certain groups remain insufficient for populations like adolescents or older adults.

---

Evidence for use in Generalized Anxiety Disorder (GAD)

Research examined Ретафил in Generalized Anxiety Disorder. The evidence is derived from short-term randomized controlled trials (8 to 10 weeks) which monitored adult patients. Researchers focused on outcomes capturing phases of heightened symptom activity, such as measuring changes in anxiety severity scores. Reported outcomes are restricted to the short-term treatment period. Long-term effects are not fully established regarding the sustained symptomatic changes over time.

---

What is Still Uncertain about Ретафил

Research to date provides context about group patterns but does not offer certainty about personal outcomes or response. A primary limitation is that long-term effects are not fully established for any studied indication, as follow-up durations were limited. The evidence quality varies across studies, and data are still emerging for complex subgroups, meaning certainty remains low in these areas.

Key Studies & References

1. Pregabalin for neuropathic pain in adults - Systematic review and meta-analysis of randomized clinical trials (Cochrane Review)
2. Pregabalin for the treatment of generalized anxiety disorder: an update (Review of efficacy and safety)
3. Pregabalin - StatPearls (Overview of FDA-approved indications and off-label use)

Common questions about Ретафил (FAQ)

---

Q: What conditions or diseases is this medicine officially used to treat?

Official regulatory documents state that theophylline, the active component of Ретафил, is indicated for the treatment of symptoms and reversible airflow obstruction. This applies to chronic lung diseases such as asthma, chronic bronchitis, and emphysema. Its primary role is in managing the ongoing tightness and constriction of the airways.

Q: Are there any long-term health consequences or side effects from taking this for years?

Regulatory documents detail that the risk of adverse reactions is linked to the concentration of the drug in the bloodstream. For patients on long-term therapy, regulatory information notes that frequent monitoring of the theophylline level in the blood is important to consider to minimize the potential risk of serious side effects that can arise from high concentrations.

Q: What are the risks of taking this medicine if I'm pregnant or breastfeeding?

According to official product information, Theophylline crosses the placenta and is also excreted into breast milk at levels similar to the mother's blood. Use requires caution, as this may potentially cause irritability or mild toxicity in a nursing infant. Clearance of the drug may also be reduced during pregnancy, which can increase the risk of side effects for the mother.

Q: What is the function of the choline part of Choline Theophyllinate?

Choline theophyllinate is essentially the choline salt form of the therapeutic drug theophylline. The official description explains that the choline component is combined with theophylline primarily to increase the drug's solubility and enhance its stability within the formulation.

Q: How quickly should I expect to feel a difference in my breathing after taking this?

Official information regarding the immediate-release forms (solutions and tablets) indicates they are absorbed rapidly, typically reaching peak concentrations in the bloodstream in about one to two hours. However, it is important to note that theophylline is not classified or used as a rescue medication for sudden, acute breathing problems.

Q: Does this medicine help with coughing or phlegm?

This medicine is indicated for the prevention and treatment of the symptoms of chronic lung conditions, including wheezing and shortness of breath. The primary mechanism of action is bronchodilation—the relaxation of the smooth muscles in the airways—which improves the overall flow of air.

Q: What should I do if I accidentally miss a dose?

Official patient information generally advises that if a dose is missed, it should be skipped. The next scheduled dose would then be taken at the usual time. Regulatory advice warns against taking two doses at the same time to compensate for a missed dose.

Official Storage and Handling Requirements

Official regulatory guidelines for Choline Theophyllinate (Ретафил) require specific storage conditions to maintain the product's stability and shelf life.

Condition	Requirement
Temperature	Store at a controlled room temperature, typically not exceeding 25 C.
Protection	Keep the medicine protected from light and moisture.
Container	Keep the product in its original container with the closure kept tightly closed.
Child Safety	Store the medicine out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Ретафил must be discarded according to established protocols for medicinal waste. Patients should utilize a designated drug take-back program or dispose of the product in accordance with local and national regulations. To protect the environment, the medicine must not be flushed down the toilet or placed in household wastewater.